Physician profile
Chad W Mcelroy
NPI 1154472355
$14,224.49
in general payments reported to CMS, 2019-2025
52 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $2,042 · 2021: $2,448 · 2022: $2,284 · 2023: $1,959 · 2024: $1,750 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,675 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,675.17 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,568.32 | 2021-2025 | |
| Lilly USA, LLC | $1,107.22 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $994.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Kowa Pharmaceuticals America, INC. | $651.98 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Novo Nordisk INC | $649.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $615.83 | 2019-2025 | Trintellix |
| Pfizer INC. | $589.45 | 2019-2025 | |
| Amarin Pharma, INC. | $569.29 | 2019-2021 | |
| Lundbeck LLC | $542.18 | 2020-2025 | Rexulti |
| Amgen INC. | $526.39 | 2019-2025 | Otezla, Repatha, Repatha |
| Optinose US, INC. | $451.06 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $431.02 | 2021-2023 | Ztlido |
| Janssen Pharmaceuticals, INC | $415.40 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $404.16 | 2024-2025 | Nuzyra, Xhance |
| Antares Pharma, INC. | $393.74 | 2019-2025 | Xyosted, Tlando, Nocdurna |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.